Pharma news
Pharma
Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir. 2 April 2020
Americas
A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug. 1 April 2020
Pharma
Gilead Sciences says it is expanding access to its experimental antiviral remdesivir for treatment of COVID-19, albeit on a limited basis. 31 March 2020
Americas
Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies. 31 March 2020
Americas
Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic. 31 March 2020
Pharma
Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19. 27 March 2020
Americas
A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19. 27 March 2020
Pharma
Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders. 26 March 2020
Americas
The Costa Rican government has asked the World Health Organization to create a voluntary pool to collect patent rights for technologies that are useful for the detection, prevention, control and treatment of the COVID-19 pandemic. 26 March 2020
Africa
Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the European Union Intellectual Property Office. 24 March 2020